MTOR and small cell lung carcinoma: Other genetic changes, such as MYC amplification or mutations of genes coding for proteins involved in cell cycle regulation, apoptosis, chromatin remodeling, or the mechanistic target of rapamycin (mTOR) signaling pathway, can also contribute to tumorigenesis and progression; however, the genetic landscape does not seem to determine SCLC subtypes [4, 5].